The DOI matches its Crossref record; 352 of the 352 references it cites were found in a registry or an index.
Fibroblast growth factors and their receptors in cancer
Abstract
FGFs (fibroblast growth factors) and their receptors (FGFRs) play essential roles in tightly regulating cell proliferation, survival, migration and differentiation during development and adult life. Deregulation of FGFR signalling, on the other hand, has been associated with many developmental syndromes, and with human cancer. In cancer, FGFRs have been found to become overactivated by several mechanisms, including gene amplification, chromosomal translocation and mutations. FGFR alterations are detected in a variety of human cancers, such as breast, bladder, prostate, endometrial and lung cancers, as well as haematological malignancies. Accumulating evidence indicates that FGFs and FGFRs may act in an oncogenic fashion to promote multiple steps of cancer progression by inducing mitogenic and survival signals, as well as promoting epithelial–mesenchymal transition, invasion and tumour angiogenesis. Therapeutic strategies targeting FGFs and FGFRs in human cancer are therefore currently being explored. In the present review we will give an overview of FGF signalling, the main FGFR alterations found in human cancer to date, how they may contribute to specific cancer types and strategies for therapeutic intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Pardo, O. E., Arcaro, A., Salerno, G., Raguz, S., Downward, J., & Seckl, M. J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.a115.109006 · Cited by 152
RetractedPardo, O. E., Arcaro, A., Salerno, G., Raguz, S., Downward, J., & Seckl, M. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109006200 · Cited by 152
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
Stratton, M. R., Campbell, P. J., & Futreal, P. A. (2009) · Nature · doi:10.1038/nature07943 · Cited by 3,449
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
Patterns of somatic mutation in human cancer genomes
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,080
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
Colotta, F., Allavena, P., Sica, A., Garlanda, C., & Mantovani, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp127 · Cited by 2,890
Fibroblast growth factor signalling: from development to cancer
Turner, N., & Grose, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2780 · Cited by 2,693
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Khan, J., Wei, J. S., Ringnér, M., Saal, L. H., Ladanyi, M., Westermann, F., Berthold, F., Schwab, M., Antonescu, C. R., Peterson, C., et al. (2001) · Nature Medicine · doi:10.1038/89044 · Cited by 2,644
Genomic instability — an evolving hallmark of cancer
Negrini, S., Gorgoulis, V. G., & Halazonetis, T. D. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2858 · Cited by 2,397
Tumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337
Genome-wide association study identifies novel breast cancer susceptibility loci
Easton, D. F., Pooley, K. A., Dunning, A. M., Pharoah, P. D. P., Thompson, D., Ballinger, D. G., Struewing, J. P., Morrison, J., Field, H., Luben, R., et al. (2007) · Nature · doi:10.1038/nature05887 · Cited by 2,319
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945
Cellular signaling by fibroblast growth factor receptors
Eswarakumar, V. P., Lax, I., & Schlessinger, J. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.001 · Cited by 1,929
Receptor Specificity of the Fibroblast Growth Factor Family
Ornitz, D. M., Xu, J., Colvin, J. S., McEwen, D. G., MacArthur, C. A., Coulier, F., Gao, G., & Goldfarb, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.25.15292 · Cited by 1,871
EMT, the cytoskeleton, and cancer cell invasion
Yilmaz, M., & Christofori, G. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9169-0 · Cited by 1,788
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
Hunter, D. J., Kraft, P., Jacobs, K. B., Cox, D. G., Yeager, M., Hankinson, S. E., Wacholder, S., Wang, Z., Welch, R., Hutchinson, A., et al. (2007) · Nature Genetics · doi:10.1038/ng2075 · Cited by 1,481
Fibroblast growth factors, their receptors and signaling
Powers, C. J., McLeskey, S. W., & Wellstein, A. (2000) · Endocrine-related cancer · doi:10.1677/erc.0.0070165 · Cited by 1,332
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies
Chin, K., DeVries, S., Fridlyand, J., Spellman, P. T., Roydasgupta, R., Kuo, W.-L., Lapuk, A., Neve, R. M., Qian, Z., Ryder, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.009 · Cited by 1,317
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis
Presta, M., Dell’Era, P., Mitola, S., Moroni, E., Ronca, R., & Rusnati, M. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.004 · Cited by 1,261
Structural and Functional Diversity in the FGf Receptor Multigene Family
(1992) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60821-0 · Cited by 1,250
Rules for Making Human Tumor Cells
Hahn, W. C., & Weinberg, R. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmra021902 · Cited by 951
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas
Bass, A. J., Watanabe, H., Mermel, C. H., Yu, S., Perner, S., Verhaak, R. G., Kim, S. Y., Wardwell, L., Tamayo, P., Gat-Viks, I., et al. (2009) · Nature Genetics · doi:10.1038/ng.465 · Cited by 942
Weiss, J., Sos, M. L., Seidel, D., Peifer, M., Zander, T., Heuckmann, J. M., Ullrich, R. T., Menon, R., Maier, S., Soltermann, A., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001451 · Cited by 821
Weinstein, I. B., & Joe, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3293 · Cited by 805
Hacohen, N., Kramer, S., Sutherland, D., Hiromi, Y., & Krasnow, M. A. (1998) · Cell · doi:10.1016/s0092-8674(00)80919-8 · Cited by 749
FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
Turner, N., Pearson, A., Sharpe, R., Lambros, M., Geyer, F., Lopez-Garcia, M. A., Natrajan, R., Marchio, C., Iorns, E., Mackay, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3746 · Cited by 732
Derailed endocytosis: an emerging feature of cancer
Mosesson, Y., Mills, G. B., & Yarden, Y. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2521 · Cited by 718
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
Cappellen, D., De Oliveira, C., Ricol, D., de Medina, S., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J. P., & Radvanyi, F. (1999) · Nature Genetics · doi:10.1038/12615 · Cited by 713
Urothelial tumorigenesis: a tale of divergent pathways
Wu, X.-R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1697 · Cited by 692
Zhan, F., Hardin, J., Kordsmeier, B., Bumm, K., Zheng, M., Tian, E., Sanderson, R., Yang, Y., Wilson, C., Zangari, M., et al. (2002) · Blood · doi:10.1182/blood.v99.5.1745 · Cited by 638
Chesi, M., Nardini, E., Brents, L. A., Schröck, E., Ried, T., Kuehl, W. M., & Bergsagel, P. L. (1997) · Nature Genetics · doi:10.1038/ng0797-260 · Cited by 637
Roles for Growth Factors in Cancer Progression
Witsch, E., Sela, M., & Yarden, Y. (2010) · Physiology · doi:10.1152/physiol.00045.2009 · Cited by 526
Smart drugs: Tyrosine kinase inhibitors in cancer therapy
Shawver, L. K., Slamon, D., & Ullrich, A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00039-9 · Cited by 522
Naski, M. C., Wang, Q., Xu, J., & Ornitz, D. M. (1996) · Nature Genetics · doi:10.1038/ng0696-233 · Cited by 498
Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) Tumors
Billerey, C., Chopin, D., Aubriot-Lorton, M.-H., Ricol, D., Gil Diez de Medina, S., Van Rhijn, B., Bralet, M.-P., Lefrere-Belda, M.-A., Lahaye, J.-B., Abbou, C. C., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64665-2 · Cited by 498
Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers
Bardelli, A., Parsons, D. W., Silliman, N., Ptak, J., Szabo, S., Saha, S., Markowitz, S., Willson, J. K. V., Parmigiani, G., Kinzler, K. W., et al. (2003) · Science · doi:10.1126/science.1082596 · Cited by 484
Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain
Mohammadi, M. (1998) · The EMBO Journal · doi:10.1093/emboj/17.20.5896 · Cited by 482
Targeting Tyrosine Kinases in Cancer: The Second Wave
Baselga, J. (2006) · Science · doi:10.1126/science.1125951 · Cited by 478
Achondroplasia is defined by recurrent G380R mutations of FGFR3.
Bellus, G. A., Hefferon, T. W., Luna, R. I. O. D., Hecht, J. T., Horton, W. A., Machado, M. A., Kaitila, I., McIntosh, I., & Francomano, C. A. (1995) · PubMed Central · Cited by 473
Somatic Mutations of the Protein Kinase Gene Family in Human Lung Cancer
Davies, H., Hunter, C., Smith, R., Stephens, P., Greenman, C., Bignell, G., Teague, J., Butler, A., Edkins, S., Stevens, C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1855 · Cited by 469
Sprouty, an intracellular inhibitor of Ras signaling
Casci, T., Vinós, J., & Freeman, M. (1999) · Cell · doi:10.1016/s0092-8674(00)80576-0 · Cited by 467
Triple-Negative Breast Cancer: Risk Factors to Potential Targets
Schneider, B. P., Winer, E. P., Foulkes, W. D., Garber, J., Perou, C. M., Richardson, A., Sledge, G. W., & Carey, L. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1208 · Cited by 437
Mohammadi, M., Honegger, A. M., Rotin, D., Fischer, R., Bellot, F., Li, W., Dionne, C. A., Jaye, M., Rubinstein, M., & Schlessinger, J. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.10.5068 · Cited by 434
Geiger, T. R., & Peeper, D. S. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.07.006 · Cited by 431
Warburton, D., El-Hashash, A., Carraro, G., Tiozzo, C., Sala, F., Rogers, O., Langhe, S. D., Kemp, P. J., Riccardi, D., Torday, J., et al. (2010) · Current Topics in Developmental Biology · doi:10.1016/s0070-2153(10)90003-3 · Cited by 421
Turner, N., Lambros, M. B., Horlings, H. M., Pearson, A., Sharpe, R., Natrajan, R., Geyer, F. C., van Kouwenhove, M., Kreike, B., Mackay, A., et al. (2010) · Oncogene · doi:10.1038/onc.2009.489 · Cited by 416
The role of FGF/Erk signaling in pluripotent cells
Lanner, F., & Rossant, J. (2010) · Development · doi:10.1242/dev.050146 · Cited by 408
Drug-Selected Human Lung Cancer Stem Cells: Cytokine Network, Tumorigenic and Metastatic Properties
Levina, V., Marrangoni, A. M., DeMarco, R., Gorelik, E., & Lokshin, A. E. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003077 · Cited by 407
Meyers, G. A., Orlow, S. J., Munro, I. R., Przylepa, K. A., & Jabs, E. W. (1995) · Nature Genetics · doi:10.1038/ng1295-462 · Cited by 390
Development trends for monoclonal antibody cancer therapeutics
Reichert, J. M., & Valge-Archer, V. E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2241 · Cited by 389
Mohammadi, M., Dikic, I., Sorokin, A., Burgess, W. H., Jaye, M., & Schlessinger, J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.3.977 · Cited by 388
Keats, J. J., Reiman, T., Maxwell, C. A., Taylor, B. J., Larratt, L. M., Mant, M. J., Belch, A. R., & Pilarski, L. M. (2003) · Blood · doi:10.1182/blood-2002-06-1675 · Cited by 382
Tomlinson, D., Baldo, O., Harnden, P., & Knowles, M. (2007) · The Journal of Pathology · doi:10.1002/path.2207 · Cited by 363
Gene expression profiling of human sarcomas: insights into sarcoma biology.
Baird, K., Davis, S., Antonescu, C. R., Harper, U. L., Walker, R. L., Chen, Y., Glatfelter, A. A., Duray, P. H., & Meltzer, P. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1699 · Cited by 353
The role of fibroblast growth factors and their receptors in prostate cancer
Kwabi-Addo, B., Ozen, M., & Ittmann, M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00535 · Cited by 350
Drug-sensitive FGFR2 mutations in endometrial carcinoma
Dutt, A., Salvesen, H. B., Chen, T.-H., Ramos, A. H., Onofrio, R. C., Hatton, C., Nicoletti, R., Winckler, W., Grewal, R., Hanna, M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803379105 · Cited by 345
FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma
Jebar, A. H., Hurst, C. D., Tomlinson, D. C., Johnston, C., Taylor, C. F., & Knowles, M. A. (2005) · Oncogene · doi:10.1038/sj.onc.1208705 · Cited by 340
Zhao, X., Weir, B. A., LaFramboise, T., Lin, M., Beroukhim, R., Garraway, L., Beheshti, J., Lee, J. C., Naoki, K., Richards, W. G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4603 · Cited by 337
Bladder Cancer in 2010: How Far have We Come?
Jacobs, B. L., Lee, C. T., & Montie, J. E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20077 · Cited by 336
Andre, F., Job, B., Dessen, P., Tordai, A., Michiels, S., Liedtke, C., Richon, C., Yan, K., Wang, B., Vassal, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1791 · Cited by 336
Hernández, S., López-Knowles, E., Lloreta, J., Kogevinas, M., Amorós, A., Tardón, A., Carrato, A., Serra, C., Malats, N., & Real, F. X. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1771 · Cited by 334
Stephens, P., Edkins, S., Davies, H., Greenman, C., Cox, C., Hunter, C., Bignell, G., Teague, J., Smith, R., Stevens, C., et al. (2005) · Nature Genetics · doi:10.1038/ng1571 · Cited by 332
FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome
Xiao, S., Nalabolu, S. R., Aster, J. C., Ma, J., Abruzzo, L., Jaffe, E. S., Stone, R., Weissman, S. M., Hudson, T. J., & Fletcher, J. A. (1998) · Nature Genetics · doi:10.1038/ng0198-84 · Cited by 323
van Rhijn, B. W. G., Vis, A. N., van der Kwast, T. H., Kirkels, W. J., Radvanyi, F., Ooms, E. C. M., Chopin, D. K., Boevé, E. R., Jöbsis, A. C., & Zwarthoff, E. C. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.073 · Cited by 322
VI, J. G. T., Cheuk, A. T., Tsang, P. S., Chung, J.-Y., Song, Y. K., Desai, K., Yu, Y., Chen, Q.-R., Shah, K., Youngblood, V., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39703 · Cited by 321
Kompier, L. C., Lurkin, I., van der Aa, M. N. M., van Rhijn, B. W. G., van der Kwast, T. H., & Zwarthoff, E. C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013821 · Cited by 315
Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele.
Bange, J., Prechtl, D., Cheburkin, Y. V., Specht, K., Harbeck, N., Schmitt, M., Knyazeva, T., Müller, S., Gärtner, S., Sures, I., et al. (2002) · PubMed · Cited by 312
Davicioni, E., Graf Finckenstein, F., Shahbazian, V., Buckley, J. D., Triche, T. J., & Anderson, M. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4578 · Cited by 308
Acevedo, V. D., Gangula, R. D., Freeman, K. W., Li, R., Zhang, Y., Wang, F., Ayala, G. E., Peterson, L. E., Ittmann, M., & Spencer, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.11.004 · Cited by 308
Pollock, P. M., Gartside, M. G., Dejeza, L. C., Powell, M. A., Mallon, M. A., Cancer Genome Project, Davies, H., Mohammadi, M., Futreal, P. A., Stratton, M. R., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210529 · Cited by 307
Integrated Profiling of Basal and Luminal Breast Cancers
Adélaïde, J., Finetti, P., Bekhouche, I., Repellini, L., Geneix, J., Sircoulomb, F., Charafe-Jauffret, E., Cervera, N., Desplans, J., Parzy, D., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2536 · Cited by 297
Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma
Lin, W. M., Baker, A. C., Beroukhim, R., Winckler, W., Feng, W., Marmion, J. M., Laine, E., Greulich, H., Tseng, H., Gates, C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2615 · Cited by 297
A Molecular Brake in the Kinase Hinge Region Regulates the Activity of Receptor Tyrosine Kinases
Chen, H., Ma, J., Li, W., Eliseenkova, A. V., Xu, C., Neubert, T. A., Miller, W. T., & Mohammadi, M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.028 · Cited by 291
Chesi, M., Brents, L. A., Ely, S. A., Bais, C., Robbiani, D. F., Mesri, E. A., Kuehl, W. M., & Bergsagel, P. L. (2001) · Blood · doi:10.1182/blood.v97.3.729 · Cited by 289
Giri, D., Ropiquet, F., & Ittmann, M. (1999) · PubMed · Cited by 280
Jang, J., Shin, K., & Park, J.-G. (2001) · PubMed · Cited by 273
Li, C., Scott, D. A., Hatch, E., Tian, X., & Mansour, S. L. (2007) · Development · doi:10.1242/dev.02701 · Cited by 273
FGFR1 Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas
Reis-Filho, J. S., Simpson, P. T., Turner, N. C., Lambros, M. B., Jones, C., Mackay, A., Grigoriadis, A., Sarrio, D., Savage, K., Dexter, T., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1164 · Cited by 270
Bakkar, A., Wallerand, H., Radvanyi, F., Lahaye, J.-B., Pissard, S., Lecerf, L., Kouyoumdjian, J. C., Abbou, C. C., Pairon, J. ‐., Jaurand, M., et al. (2003) · PubMed · Cited by 270
FGFR2 -Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival
Kunii, K., Davis, L., Gorenstein, J., Hatch, H., Yashiro, M., Di Bacco, A., Elbi, C., & Lutterbach, B. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5229 · Cited by 269
Kan, S.-H., Elanko, N., Johnson, D., Cornejo-Roldan, L., Cook, J., Reich, E. W., Tomkins, S., Verloes, A., Twigg, S. R. F., Rannan-Eliya, S., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/338758 · Cited by 265
Desnoyers, L. R., Pai, R., Ferrando, R. E., Hötzel, K., Le, T., Ross, J., Carano, R., D'Souza, A., Qing, J., Mohtashemi, I., et al. (2008) · Oncogene · doi:10.1038/sj.onc.1210623 · Cited by 264
Promotion and Attenuation of FGF Signaling Through the Ras-MAPK Pathway
Tsang, M., & Dawid, I. B. (2004) · Science's STKE · doi:10.1126/stke.2282004pe17 · Cited by 262
Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome
Yu, K., Herr, A. B., Waksman, G., & Ornitz, D. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.26.14536 · Cited by 258
Wilkie, A. O. M. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.03.001 · Cited by 255
Role of FGF10/FGFR2b signaling during mammary gland development in the mouse embryo
Mailleux, A. A., Spencer-Dene, B., Dillon, C., Ndiaye, D., Savona-Baron, C., Itoh, N., Kato, S., Dickson, C., Thiery, J. P., & Bellusci, S. (2002) · Development · doi:10.1242/dev.129.1.53 · Cited by 255
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
Qing, J., Du, X., Chen, Y., Chan, P., Li, H., Wu, P., Marsters, S., Stawicki, S., Tien, J., Totpal, K., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38017 · Cited by 255
Veltman, J. A., Fridlyand, J., Pejavar, S., Olshen, A. B., Korkola, J. E., DeVries, S., Carroll, P. R., Kuo, W. L., Pinkel, D., Albertson, D. G., et al. (2003) · PubMed · Cited by 251
8p11 myeloproliferative syndrome: a review
Jackson, C. C., Medeiros, L. J., & Miranda, R. N. (2010) · Human Pathology · doi:10.1016/j.humpath.2009.11.003 · Cited by 247
Anderson, J. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.9.1475 · Cited by 247
Yamaguchi, F., Saya, H., Bruner, J. M., & Morrison, R. S. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.2.484 · Cited by 245
Wachtel, M., Dettling, M., Koscielniak, E., Stegmaier, S., Treuner, J., Simon-Klingenstein, K., Bühlmann, P., Niggli, F. K., & Schäfer, B. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0844 · Cited by 244
Adnane, J., Gaudray, P., Ca, D., Crumley, G., Jaye, M., Schlessinger, J., Jeanteur, P., Birnbaum, D., & Theillet, C. G. (1991) · PubMed · Cited by 240
Cao, L., Yu, Y., Bilke, S., Walker, R. L., Mayeenuddin, L. H., Azorsa, D. O., Yang, F., Pineda, M., Helman, L. J., & Meltzer, P. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0582 · Cited by 239
Courjal, F., Cuny, M., Simony-Lafontaine, J., Louason, G., Speiser, P., Zeillinger, R., Rodríguez, C., & Theillet, C. G. (1997) · PubMed · Cited by 238
Comprehensive Profiling of 8p11-12 Amplification in Breast Cancer
Gelsi-Boyer, V., Orsetti, B., Cervera, N., Finetti, P., Sircoulomb, F., Rougé, C., Lasorsa, L., Letessier, A., Ginestier, C., Monville, F., et al. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0128 · Cited by 234
Sprouty proteins, masterminds of receptor tyrosine kinase signaling
Cabrita, M. A., & Christofori, G. (2008) · Angiogenesis · doi:10.1007/s10456-008-9089-1 · Cited by 229
van Rhijn, B. W. G., van der Kwast, T. H., Vis, A. N., Kirkels, W. J., Boevé, E. R., Jöbsis, A. C., & Zwarthoff, E. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2421 · Cited by 227
Expression of fgf and fgf receptor genes in human breast cancer
Penault‐Llorca, F., Bertucci, F., Adélaïde, J., Parc, P., Coulier, F., Jacquemier, J., Birnbaum, D., & Delapeyrière, O. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910610205 · Cited by 226
Marek, L., Ware, K. E., Fritzsche, A., Hercule, P., Helton, W. R., Smith, J. E., McDermott, L. A., Coldren, C. D., Nemenoff, R. A., Merrick, D. T., et al. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.049544 · Cited by 222
Molecular cytogenetic analysis of 11 new breast cancer cell lines
Forozan, F., Veldman, R., Ammerman, C. A., Parsa, N. Z., Kallioniemi, A., Kallioniemi, O.-P., & Ethier, S. P. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6695007 · Cited by 219
Gene amplifications associated with the development of hormone-resistant prostate cancer.
Edwards, J., Krishna, N. S., Witton, C. J., & Bartlett, J. M. S. (2003) · PubMed · Cited by 213
Mutations in different components of FGF signaling in LADD syndrome
Rohmann, E., Brunner, H. G., Kayserili, H., Uyguner, O., Nürnberg, G., Lew, E. D., Dobbie, A., Eswarakumar, V. P., Uzumcu, A., Ulubil-Emeroglu, M., et al. (2006) · Nature Genetics · doi:10.1038/ng1757 · Cited by 211
Richelda, R., Ronchetti, D., Baldini, L., Cro, L., Viggiano, L., Marzella, R., Rocchi, M., Otsuki, T., Lombardi, L., Maiolo, A. T., et al. (1997) · Blood · doi:10.1182/blood.v90.10.4062 · Cited by 206
Goriely, A., Hansen, R. M. S., Taylor, I. B., Olesen, I. A., Jacobsen, G. K., McGowan, S. J., Pfeifer, S. P., McVean, G. A. T., Meyts, E. R.-D., & Wilkie, A. O. M. (2009) · Nature Genetics · doi:10.1038/ng.470 · Cited by 205
Memarzadeh, S., Xin, L., Mulholland, D. J., Mansukhani, A., Wu, H., Teitell, M. A., & Witte, O. N. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.11.002 · Cited by 201
Popovici, C., Zhang, B., Grégoire, M.-J., Jonveaux, P., Lafage-Pochitaloff, M., Birnbaum, D., & Pébusque, M.-J. (1999) · Blood · doi:10.1182/blood.v93.4.1381 · Cited by 201
De-regulated FGF receptors as therapeutic targets in cancer
Knights, V., & Cook, S. J. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.10.001 · Cited by 196
Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas
Mao, X., Orchard, G., Lillington, D. M., Russell-Jones, R., Young, B. D., & Whittaker, S. J. (2003) · Blood · doi:10.1182/blood-2002-08-2434 · Cited by 194
Ho, H. K., Pok, S., Streit, S., Ruhe, J. E., Hart, S., Lim, K. S., Loo, H. L., Aung, M. O., Lim, S. G., & Ullrich, A. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.08.015 · Cited by 192
Olsen, S. K., Ibrahimi, O. A., Raucci, A., Zhang, F., Eliseenkova, A. V., Yayon, A., Basilico, C., Linhardt, R. J., Schlessinger, J., & Mohammadi, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307287101 · Cited by 192
Demiroglu, A., Steer, E. J., Heath, C., Taylor, K., Bentley, M., Allen, S. L., Koduru, P., Brody, J. P., Hawson, G., Rodwell, R., et al. (2001) · Blood · doi:10.1182/blood.v98.13.3778 · Cited by 189
Frequent FGFR3 mutations in urothelial papilloma
van Rhijn, B. W. G., Montironi, R., Zwarthoff, E. C., Jöbsis, A. C., & van der Kwast, T. H. (2002) · The Journal of Pathology · doi:10.1002/path.1202 · Cited by 189
Pardo, O. E., Wellbrock, C., Khanzada, U. K., Aubert, M., Arozarena, I., Davidson, S., Bowen, F., Parker, P. J., Filonenko, V. V., Gout, I. T., et al. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601198 · Cited by 183
Hara, T., Ooi, A., Kobayashi, M., Mai, M., Yanagihara, K., & Nakanishi, I. (1998) · PubMed · Cited by 183
Robertson, S. C., Meyer, A. N., Hart, K. C., Galvin, B. D., Webster, M. K., & Donoghue, D. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4567 · Cited by 181
Lamont, F. R., Tomlinson, D. C., Cooper, P. A., Shnyder, S. D., Chester, J. D., & Knowles, M. A. (2011) · British Journal of Cancer · doi:10.1038/sj.bjc.6606016 · Cited by 180
Li, Z. G., Mathew, P., Yang, J., Starbuck, M. W., Zurita, A. J., Liu, J., Sikes, C., Multani, A. S., Efstathiou, E., Lopez, A., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33093 · Cited by 180
FRS2α attenuates FGF receptor signaling by Grb2- mediated recruitment of the ubiquitin ligase Cbl
Wong, A., Lamothe, B., Lee, A., Schlessinger, J., & Lax, I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052138899 · Cited by 177
Avet‐Loiseau, H., Li, J., Facon, T. T. F., Brigaudeau, C., Morineau, N., Maloisel, F., Rapp, M.-J., Talmant, P., Trimoreau, F., Jaccard, A., et al. (1998) · PubMed · Cited by 177
Bellus, G. A., Spector, E. B., Speiser, P. W., Weaver, C. A., Garber, A. T., Bryke, C. R., Israel, J., Rosengren, S. S., Webster, M. K., Donoghue, D. J., et al. (2000) · The American Journal of Human Genetics · doi:10.1086/316892 · Cited by 174
Lopez-Knowles, E., Hernandez, S., Malats, N., Kogevinas, M., Lloreta, J., Carrato, A., Tardon, A., Serra, C., & Real, F. X. (2006) · European Urology Supplements · doi:10.1016/s1569-9056(06)61338-9 · Cited by 173
Reiter, A., Sohal, J., Kulkarni, S., Chase, A., Macdonald, D. H. C., Aguiar, R. C. T., Gonçalves, C., Hernandez, J. M., Jennings, B. A., Goldman, J. M., et al. (1998) · Blood · doi:10.1182/blood.v92.5.1735 · Cited by 172
Webster, M. K., d’Avis, P. Y., Robertson, S. C., & Donoghue, D. J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.8.4081 · Cited by 172
Gorringe, K. L., Jacobs, S., Thompson, E. R., Sridhar, A., Qiu, W., Choong, D. Y. H., & Campbell, I. G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0502 · Cited by 171
Chen, J., DeAngelo, D. J., Kutok, J. L., Williams, I. R., Lee, B. H., Wadleigh, M., Duclos, N., Cohen, S., Adelsperger, J., Okabe, R., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404438101 · Cited by 171
The transmembrane protein XFLRT3 forms a complex with FGF receptors and promotes FGF signalling
Böttcher, R. T., Pollet, N., Delius, H., & Niehrs, C. (2004) · Nature Cell Biology · doi:10.1038/ncb1082 · Cited by 170
Plowright, E. E., Li, Z., Bergsagel, P. L., Chesi, M., Barber, D. L., Branch, D. R., Hawley, R. G., & Stewart, A. K. (2000) · Blood · doi:10.1182/blood.v95.3.992.003k29_992_998 · Cited by 165
Freier, K., Schwaenen, C., Sticht, C., Flechtenmacher, C., Mühling, J., Hofele, C., Radlwimmer, B., Lichter, P., & Joos, S. (2007) · Oral Oncology · doi:10.1016/j.oraloncology.2006.01.005 · Cited by 165
Lax, I., Wong, A., Lamothe, B., Lee, A., Frost, A., Hawes, J., & Schlessinger, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00689-5 · Cited by 165
A 1 Mb minimal amplicon at 8p11–12 in breast cancer identifies new candidate oncogenes
Garcia, M. J., Pole, J. C. M., Chin, S.-F., Teschendorff, A., Naderi, A., Ozdag, H., Vias, M., Kranjac, T., Subkhankulova, T., Paish, C., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208741 · Cited by 164
Smoking and cancer‐related gene expression in bronchial epithelium and non‐small‐cell lung cancers
Woenckhaus, M., Klein‐Hitpaß, L., Grepmeier, U., Merk, J., Pfeifer, R., Wild, P. J., Bettstetter, M., Wuensch, P. H., Blaszyk, H., Hartmann, A., et al. (2006) · The Journal of Pathology · doi:10.1002/path.2039 · Cited by 163
Simon, R., Richter, J., Wagner, U. A., Fijan, A., Bruderer, J., Schmid, U., Ackermann, D., Maurer, R. E., Alund, G., Knönagel, H., et al. (2001) · PubMed · Cited by 162
Lew, E. D., Furdui, C. M., Anderson, K. S., & Schlessinger, J. (2009) · Science Signaling · doi:10.1126/scisignal.2000021 · Cited by 162
FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer
Nomura, S., Yoshitomi, H., Takano, S., Shida, T., Kobayashi, S., Ohtsuka, M., Kimura, F., Shimizu, H., Yoshidome, H., Kato, A., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604473 · Cited by 161
Pardo, O. E., Latigo, J., Jeffery, R. E., Nye, E., Poulsom, R., Spencer-Dene, B., Lemoine, N. R., Stamp, G. W., Aboagye, E. O., & Seckl, M. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1576 · Cited by 160
Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas
Rand, V., Huang, J., Stockwell, T., Ferriera, S., Buzko, O., Levy, S., Busam, D., Li, K., Edwards, J. B., Eberhart, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507200102 · Cited by 159
Wang, J., Stockton, D. W., & Ittmann, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0408 · Cited by 158
Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b
Bernard‐Pierrot, I., Brams, A., Dunois-Lardé, C., Caillault, A., de Medina, S. G. D., Cappellen, D., Graff, G., Thiery, J. P., Chopin, D. K., Ricol, D., et al. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi290 · Cited by 157
Xian, W., Schwertfeger, K. L., Vargo-Gogola, T. C., & Rosen, J. M. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200505098 · Cited by 155
van Rhijn, B. V., van Tilborg, A. V., Lurkin, I., Bonaventure, J., de Vries, A., Thiery, J., van der Kwast, T., Zwarthoff, E., & Radvanyi, F. (2002) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5200883 · Cited by 155
FGFRI and PLAT genes and DNA amplification at 8p 12 in breast and ovarian cancers
Theillet, C. G., Adélaı̈de, J., Louason, G., Bonnet‐Dorion, F., Jacquemier, J. D., Adnane, J., Longy, M., Katsaros, D., Sismondi, P., Gaudray, P., et al. (1993) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870070407 · Cited by 154
Kovalenko, D., Yang, X., Nadeau, R. J., Harkins, L. K., & Friesel, R. E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200606200 · Cited by 153
Roumiantsev, S., Krause, D. S., Neumann, C. A., Dimitri, C. A., Asiedu, F., Cross, N. C. P., & Etten, R. A. V. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00053-4 · Cited by 152
DORKIN, T. J., Robinson, M. C., Marsh, C., Bjartell, A., Neal, D. E., & Leung, H. Y. (1999) · Oncogene · doi:10.1038/sj.onc.1202624 · Cited by 152
Bai, A., Meetze, K. A., Vo, N. N. Y., Kollipara, S., Mazsa, E. K., Winston, W. M., Weiler, S., Poling, L. L., Chen, T., Ismail, N. S., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1489 · Cited by 151
Byron, S. A., Gartside, M. G., Wellens, C. L., Mallon, M. A., Keenan, J. B., Powell, M. A., Goodfellow, P. J., & Pollock, P. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0770 · Cited by 149
Popovici, C., Adélaïde, J., Ollendorff, V., Chaffanet, M., Guasch, G., Jacrot, M., Leroux, D., Birnbaum, D., & Pébusque, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.10.5712 · Cited by 146
Lajeunie, E., Heuertz, S., Ghouzzi, V. E., Martinovic, J., Rénier, D., Merrer, M. F. L., & Bonaventure, J. (2006) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201558 · Cited by 145
Inducible dimerization of FGFR1
Welm, B. E., Freeman, K. W., Chen, M., Contreras, A., Spencer, D. M., & Rosen, J. M. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200107119 · Cited by 145
Bovée, J. V. M. G., den Broek, L. J. C. M. V., Cleton-Jansen, A., & Hogendoorn, P. C. W. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780202 · Cited by 145
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells
Trudel, S., Stewart, A. K., Rom, E., Wei, E. N., Li, Z. H., Kotzer, S., Chumakov, I., Singer, Y., Chang, H., Liang, S., et al. (2006) · Blood · doi:10.1182/blood-2005-10-4179 · Cited by 143
Amplification of fgfr4 gene in human breast and gynecological cancers
Jaakkola, S., Salmikangas, P., Nylund, S. J., Lehtovirta, P., Nevanlinna, H. A., Partanen, J. M., Armstrong, E., & Pyrhönen, S. O. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910540305 · Cited by 142
Guasch, G., Mack, G. J., Popovici, C., Dastugue, N., Birnbaum, D., Rattner, J. B., & Pébusque, M. (2000) · Blood · doi:10.1182/blood.v95.5.1788.005k15_1788_1796 · Cited by 141
Letessier, A., Sircoulomb, F., Ginestier, C., Cervera, N., Monville, F., Gelsi‐Boyer, V., Esterni, B., Geneix, J., Finetti, P., Zemmour, C., et al. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-245 · Cited by 139
Haugsten, E. M., Małecki, J., Bjørklund, S. M. S., Olsnes, S., & Wesche, J. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-12-1219 · Cited by 139
Self-citationTomlinson, D. C., Lamont, F. R., Shnyder, S. D., & Knowles, M. A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2816 · Cited by 138
Aberrant expression of type I fibroblast growth factor receptor in human pancreatic adenocarcinomas.
Kobrin, M. S., Yamanaka, Y., Friess, H., Lopez, M. E., & Korc, M. (1993) · PubMed · Cited by 138
Straume, O., & Akslen, L. A. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64922-x · Cited by 135
Tumor Angiogenesis: Insights and Innovations
Nussenbaum, F., & Herman, I. M. (2010) · Journal of Oncology · doi:10.1155/2010/132641 · Cited by 134
The binding of NCAM to FGFR1 induces a specific cellular response mediated by receptor trafficking
Francavilla, C., Cattaneo, P., Berezin, V., Bock, E., Ami, D., de Marco, A., Christofori, G., & Cavallaro, U. (2009) · The Journal of Cell Biology · doi:10.1083/jcb.200903030 · Cited by 133
Genomic and Expression Analysis of the 8p11–12 Amplicon in Human Breast Cancer Cell Lines
Ray, M. E., Yang, Z. Q., Albertson, D. G., Kleer, C. G., Washburn, J. G., Macoska, J. A., & Ethier, S. P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1022 · Cited by 132
FGFR4 Arg388 Allele Is Associated With Resistance to Adjuvant Therapy in Primary Breast Cancer
Thussbas, C., Nährig, J., Streit, S., Bange, J., Kriner, M., Kates, R. E., Ulm, K., Kiechle, M. B., Hoefler, H., Ullrich, A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.8587 · Cited by 131
Gauglhofer, C., Sagmeister, S., Schrottmaier, W. C., Fischer, C., Rodgarkia‐Dara, C., Mohr, T. T., Stättner, S., Bichler, C., Kandioler, D., Wrba, F., et al. (2010) · Hepatology · doi:10.1002/hep.24099 · Cited by 130
Voortman, J., Lee, J., Killian, J. K., Suuriniemi, M., Wang, Y., Lucchi, M., Smith, W. I., Meltzer, P. S., Wang, Y., & Giaccone, G. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008132107 · Cited by 129
Ibrahimi, O. A. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddh011 · Cited by 128
Terminal end bud maintenance in mammary gland is dependent upon FGFR2b signaling
Parsa, S., Ramasamy, S. K., Langhe, S. D., Gupte, V. V., Haigh, J. J., Medina, D., & Bellusci, S. (2008) · Developmental Biology · doi:10.1016/j.ydbio.2008.02.014 · Cited by 128
Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer
Tomlinson, D. C., Hurst, C. D., & Knowles, M. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210399 · Cited by 128
Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia
Cho, J. Y., Guo, C., Torello, M., Lunstrum, G. P., Iwata, T., Deng, C., & Horton, W. A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2237184100 · Cited by 128
Fibroblast Growth Factor Receptors as Molecular Targets in Thyroid Carcinoma
Bernard, R. S., Zheng, L., Liu, W., Winer, D. A., Asa, S. L., & Ezzat, S. (2004) · Endocrinology · doi:10.1210/en.2004-1134 · Cited by 126
Different intracellular trafficking of FGF1 endocytosed by the four homologous FGF receptors
Haugsten, E. M., Sørensen, V., Brech, A., Olsnes, S., & Wesche, J. (2005) · Journal of Cell Science · doi:10.1242/jcs.02509 · Cited by 126
Self-citationTherapeutic targeting of the prostate cancer microenvironment
Κάρλου, Μ., Tzelepi, V., & Efstathiou, E. (2010) · Nature Reviews Urology · doi:10.1038/nrurol.2010.134 · Cited by 123
Kadota, M., Sato, M., Duncan, B., Ooshima, A., Yang, H. H., Diaz-Meyer, N., Gere, S., Kageyama, S., Fukuoka, J., Nagata, T., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0064 · Cited by 123
Morrison, R. S., Yamaguchi, F., Saya, H., Bruner, J. M., Yahanda, A. M., Donehower, L. A., & Berger, M. S. (1994) · Journal of Neuro-Oncology · doi:10.1007/bf01328955 · Cited by 121
Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma
Gartside, M. G., Chen, H., Ibrahimi, O. A., Byron, S. A., Curtis, A. V., Wellens, C. L., Bengston, A., Yudt, L. M., Eliseenkova, A. V., Ma, J., et al. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0021 · Cited by 121
Ronchetti, D., Greco, A., Compasso, S., Colombo, G., Dell'Era, P., Otsuki, T., Lombardi, L., & Neri, A. (2001) · Oncogene · doi:10.1038/sj.onc.1204465 · Cited by 119
Immunohistochemical detection of K-sam protein in stomach cancer.
Hattori, Y., Itoh, H., Uchino, S., Hosokawa, K., Ochiai, A., Ino, Y., Ishii, H., Sakamoto, H., Yamaguchi, N., Yanagihara, K., et al. (1996) · PubMed · Cited by 119
Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases
Abella, J. V., & Park, M. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90857.2008 · Cited by 118
Selective over‐expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer
Sahadevan, K., Darby, S., Leung, H. Y., Mathers, M. E., Robson, C. N., & Gnanapragasam, V. J. (2007) · The Journal of Pathology · doi:10.1002/path.2205 · Cited by 115
Berger, W., Setinek, U., Mohr, T. T., Kindås-Mügge, I., Vetterlein, M., Dekan, G., Eckersberger, F., Caldas, C. H., & Micksche, M. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19991029)83:3<415::aid-ijc19>3.0.co;2-y · Cited by 115
Pardo, O. E., Lesay, A., Arcaro, A., Lopes, R., Ng, B. L., Warne, P. H., McNeish, I. A., Tetley, T. D., Lemoine, N. R., Mehmet, H., et al. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.21.7600-7610.2003 · Cited by 115
Molecular and Cellular Biology of Rhabdomyosarcoma
Giovanni, C. D., Landuzzi, L., Nicoletti, G., Lollini, P., & Nanni, P. (2009) · Future Oncology · doi:10.2217/fon.09.97 · Cited by 113
Rieger‐Christ, K., Mourtzinos, A. P., Lee, P. J., Zagha, R. M., Cain, J. E., Silverman, M. L., Libertino, J. A., & Summerhayes, I. C. (2003) · Cancer · doi:10.1002/cncr.11536 · Cited by 109
Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma
Streit, S., Bange, J., Fichtner, A., Ihrler, S., Issing, W. J., & Ullrich, A. (2004) · International Journal of Cancer · doi:10.1002/ijc.20204 · Cited by 109
Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma
Sibley, K., Heavens, D., & Knowles, M. A. (2001) · Oncogene · doi:10.1038/sj.onc.1204110 · Cited by 108
Missiaglia, E., Selfe, J., Hamdi, M., Williamson, D., Schaaf, G., Fang, C., Köster, J., Summersgill, B. M., Messahel, B., Versteeg, R., et al. (2009) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20655 · Cited by 108
Behrens, C., Lin, H. Y., Lee, J. J., Raso, M. G., Hong, W. K., Wistuba, I. I., & Lotan, R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0167 · Cited by 108
Smedley, D. P., Hamoudi, R., Clark, J., Warren, W., Abdul-Rauf, M., Somers, G., Venter, D., Fagan, K., Cooper, C., & Shipley, J. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.4.637 · Cited by 106
FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities
Allerstorfer, S., Sonvilla, G., Fischer, H., Spiegl‐Kreinecker, S., Gauglhofer, C., Setinek, U., Czech, T., Marosi, C., Buchroithner, J., Pichler, J., et al. (2008) · Oncogene · doi:10.1038/onc.2008.61 · Cited by 105
Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome
Grand, E., Grand, F., Chase, A., Ross, F., Corcoran, M., Oscier, D., & Cross, N. (2004) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20023 · Cited by 105
Gowardhan, B., Douglas, D. A., Mathers, M. E., McKie, A. B., McCracken, S. R., Robson, C. N., & Leung, H. Y. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602274 · Cited by 105
Cited by
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
Singh, D., Chan, J. M., Zoppoli, P., Niola, F., Sullivan, R., Castano, A., Liu, E. M., Reichel, J., Porrati, P., Pellegatta, S., et al. (2012) · Science · doi:10.1126/science.1220834 · Cited by 789
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
Wu, Y.-M., Su, F., Kalyana-Sundaram, S., Khazanov, N., Ateeq, B., Cao, X., Lonigro, R. J., Vats, P., Wang, R., Lin, S.-F., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0050 · Cited by 744
Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors
Roskoski, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.01.003 · Cited by 607
Targeting FGFR Signaling in Cancer
Touat, M., Ileana, E., Postel-Vinay, S., André, F., & Soria, J.-C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2329 · Cited by 524
Current developments of coumarin-based anti-cancer agents in medicinal chemistry
Emami, S., & Dadashpour, S. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.08.033 · Cited by 504
Metadata
- Authors
- Wesche, J., Haglund, K., & Haugsten, E. M.
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 2011-06-28
- Volume
- 437
- Issue
- 2
- Pages
- 199-213
- ISSN
- 0264-6021 (ISSN-L)
- 1470-8728
- OpenAlex
- W2113727201
- Cited by
- 534
- References
- 352
- FWCI
- 17.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.